BociMed Closed CNY 100 Mn in A New Financing Round

Healthcare Author: Lingxi Peng Feb 16, 2023 12:16 PM (GMT+8)

After this financing, BociMed will implement business restructuring and specify the focus of subsidiary and parent company

DNA, small molecule

BociMed (Chinese: 博志研新) announced that it had completed a new equity financing, which was led by Guoxin Investment (Chinese: 国鑫投资). Proceeds raised in this funding round will mainly be used in the R&D of improved new drugs, promote the clinical development and commercialization of multiple new drugs including BCM335, BCM331, BCM291, BCM332, BCM345, and BCM347. It is expected that by the end of 2023, the company's fastest-moving improved new drug will submit NDA applications to the NMPA and FDA simultaneously.

Founded in 2012, BociMed is a biotech focusing on the development of innovative drugs and leading therapies. The pipelines mainly cover CNS, anti-tumor, ophthalmology, and respiratory. BociMed also provides integrated small molecule CRO/CDMO services for clients, including the upstream small molecule manufacturing, CMC services, diversified drug delivery services, and the downstream clinical study services. 

With two internal R&D centers settled in Shanghai and Nanjing, and a subsidiary clinical company in Chengdu, BociMed now established a professional drug delivery technology platform which includes oral administration, parenteral administration, mucosal administration, ophthalmic administration, and transdermal administration. Besides, BociMed has put efforts in the R&D of  RNA delivery technology (exosomes, liposomes). Now Bocimed has more than 100 product development technologies and nearly 170 applied intellectual properties (52 authorized), focusing on various therapeutic areas including oncology, cardiovascular science, immunology, neurological and mental health.

Currently, BociMed is deploying business restructuring plan. After this restructuring, the parent company will focus on the R&D of innovative drugs and new therapies, and promote the development and commercialization of more than 20 new drugs including BCM335、BCM331、BCM291、BCM332、BCM345、BCM347, of which 9 improved drugs have submitted IND and 3 have completed clinical trial enrollment. The subsidiary will continue to deepen CRO/CDMO integrated services.

BociMed's competitors include HwaGen (Chinese: 华先医药), Porton (Chinese: 博腾生物), and Sinopep (Chinese: 诺泰生物).